Atriva Therapeutics GmbH

https://www.atriva-therapeutics.com

Atriva Therapeutics, founded in 2015, is a biopharmaceutical company pioneering the development of host-targeting antiviral therapies setup by a team of leading scientists in viral research and seasoned industry experts. The company aims to develop new antiviral therapies against different respiratory viral infections. Atriva’s lead product ATR-002 is a first-in-class host-targeting agent, inhibiting viral replication in influenza and other respiratory infections, an area of high unmet medical need. The Company owns five broad patent families with broad coverage related to the use of MEK inhibitors for anti-viral therapies and late expiry in 2038. Atriva was a winner of the German 2016 Science4Live business plan concept contest. Atriva Therapeutics is located in Tübingen, Germany. *

	Start	2015-05-21 established
	Predecessor	University of Tübingen (Eberhard-Karls-Universität)
	Industry	virostatic agent
	Industry 2	zapnometinib (ATR-002)
	Person	Pangratz, Christian M. (Atriva Therapeutics 202301– CEO before Sterna Biologicals + Secarna + Vectura + Sykepharma)
	Person 2	Lichtenberger, Rainer (Atriva 201606–2023 CEO + Co-Founder before Cevec + Merckle/ratiopharm + Merck KGaA RETIRED 2023)

	Region	Martinsried
	Country	Germany
	Street	19 Am Klopferspitz
	City	82152 Martinsried
	Tel	+49-69-9999-16219
		Address record changed: 2023-07-29

Basic data	Employees	n. a.

		* Document for »About Section«: Atriva Therapeutics GmbH. (1/3/19). "Press Release: Atriva Therapeutics Announces First Closing of Series A Financing Round". Tübingen.

		Record changed: 2024-12-29